Clinical-MRI correlations in the secondary progressive phase of MS: lessons from the treatment trials

被引：2
|
作者：
Clanet, M
Cassol, E
Manelfe, C
Berry, I
机构：
[1] Univ Hosp, Dept Neurol, Toulouse, France
[2] Univ Hosp, Dept Neuroradiol, F-31403 Toulouse 4, France
[3] Univ Hosp, Dept Biophys, F-31403 Toulouse, France
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2003年 / 206卷 / 02期
关键词：
clinical-MRI correlation; multiple sclerosis; treatment trials;
D O I：
10.1016/S0022-510X(02)00351-9
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Conventional MRI techniques are sensitive to detect MS lesions and their change overtime. In relapsing-remitting MS correlations with clinical measures are weak suggesting a pathological heterogeneity of these lesions. There are less data available in secondary progressive phase of the disease. The best source for clinical MRI correlations analysis is the placebo arm of the published interferon beta trials. This review presents the main clinical-MRI findings from these trials then focuses on recent promising observations obtained with non conventional MRI techniques in SP MS patients. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：139 / 144
页数：6
相关论文
共 50 条
  • [31] Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis
    McAdams, Matthew
    Stankiewicz, James M.
    Weiner, Howard L.
    Chitnis, Tanuja
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 54
  • [32] TREATMENT OF ISCHEMIC STROKE - LESSONS FROM CLINICAL-TRIALS
    GORELICK, PB
    [J]. POSTGRADUATE MEDICINE, 1989, 86 (08) : 107 - 118
  • [33] MRI-clinical correlations in the primary progressive course of MS: new insights into the disease pathophysiology from the application of magnetization transfer, diffusion tensor, and functional MRI
    Filippi, M
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 206 (02) : 157 - 164
  • [34] Linomide in relapsing and secondary progressive MS -: Part II:: MRI results
    Wolinsky, JS
    Narayana, PA
    Noseworthy, JH
    Lublin, FD
    Whitaker, JN
    Linde, A
    Gjörstrup, P
    Sullivan, HC
    [J]. NEUROLOGY, 2000, 54 (09) : 1734 - 1741
  • [35] Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy
    Shoeibi, Ali
    Olfati, Nahid
    Litvan, Irene
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2018, 27 (04) : 349 - 361
  • [36] Correlation of multiple sclerosis Impairment scale (MSIS) with clinical and MRI outcomes in secondary progressive MS in comparison to EDSS
    Theodorsdottir, A.
    Larsen, P. V.
    Nielsen, H. H.
    Illes, Z.
    Ravnborg, M. H.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 268 - 268
  • [37] Treatment trials in progressive MS—current challenges and future directions
    Marcus W. Koch
    Gary Cutter
    Peter K. Stys
    V. Wee Yong
    Luanne M. Metz
    [J]. Nature Reviews Neurology, 2013, 9 : 496 - 503
  • [38] Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
    Van Acker, Heleen. H.
    Anguille, Sebastien
    Willemen, Yannick
    Smits, Evelien L.
    Van Tendeloo, Viggo F.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2016, 158 : 24 - 40
  • [39] Lessons From Recent Randomized Clinical Trials of Binocular Treatment for Amblyopia
    Holmes, Jonathan M.
    [J]. JAMA OPHTHALMOLOGY, 2018, 136 (02) : 181 - 183
  • [40] Lessons Learned from Clinical Trials in Acute Heart Failure: Phase 3 Drug Trials
    O'Connor, Christopher M.
    Fiuzat, Mona
    [J]. HEART FAILURE CLINICS, 2011, 7 (04) : 451 - +
12345